Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap731.12K
Enterprise Value-2.08M
VRAX
(NASDAQ)Virax Biolabs Group Limited
$0.24-- (--)
Loading... - Market loading
Virax Biolabs Group (VRAX) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)8.32
Price/Book (mrq)0.14
Price/Tangible Book (mrq)0.14
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue-23.63
EV/Earnings0.17
EV/EBITDA0.17
EV/EBIT0.34
EV/FCF0.18
Stock Price
Current price, 52-week range, and moving averages
Current Price$0.24
1-Day Change53.09%
52-Week High$1.20
52-Week Low$0.10
52-Week Change-86.07%
YTD Change-38.80%
1-Year Change-78.06%
50-Day MA$0.16
200-Day MA$0.42
Avg Volume (30 day)45.43M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding4.76M
Book Value per Share$1.12
Net Cash per Share$0.59
FCF per Share$-2.41
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin-259.98%
EBITDA Margin (ttm)-13656.31%
EBIT Margin (ttm)-7014.61%
Operating Margin (ttm)-14271.46%
Pretax Margin (ttm)-14393.31%
Profit Margin (ttm)-13913.25%
FCF Margin (ttm)-13068.40%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-230.12%
Return on Assets (ttm)-213.89%
Return on Invested Capital (ttm)-194.40%
Return on Capital Employed (ttm)-115.20%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue87.86K
Gross Profit-228.41K
Operating Income-12.54M
Pretax Income-12.65M
Net Income-12.22M
EBITDA-12.00M
EBIT-6.16M
Diluted EPS$-3.38
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-10.28M
Capital Expenditures1.21M
Free Cash Flow-11.48M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-95.95%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)5.72M
Cash & Securities (mrq)3.35M
Net Cash (mrq)2.81M
Net Cash per Share$0.59
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)537.99K
Working Capital (mrq)3.78M
Total Equity (mrq)5.31M
Book Value per Share$1.12
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)11.35
Quick Ratio (mrq)11.21
Debt/Equity (mrq)0.10
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-1671.94%
FCF Yield-1570.42%
Buyback Yield-566.45%
Total Shareholder Yield-566.45%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-9.57
Piotroski F-Score2/9
Frequently Asked Questions About Virax Biolabs Group Statistics
What are the key financial metrics for VRAX?
Virax Biolabs Group Limited (VRAX) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is VRAX's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Virax Biolabs Group is overvalued or undervalued.
How do I read VRAX's profitability ratios?
Virax Biolabs Group's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do VRAX's debt ratios indicate?
The financial health section shows Virax Biolabs Group's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is VRAX's dividend analysis?
The dividend section covers Virax Biolabs Group's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.